Heart failure & cardiomyopathies

OPTImal PHARMacological Therapy for Patients with Heart Failure: Rationale and Design of the OPTIPHARM-HF Registry

Eur J Heart FailPublished 23 Jun 2024Design and rationale of a prospective observational registry

Read the original article ↗PubMed

Cite

Study context

Population: Adults with symptomatic heart failure (HF) regardless of EF, outpatients and inpatients with chronic and acute decompensated HF, ≈35 Italian HF centresplanned up to 2500

Primary endpoint: Prevalence of guideline-directed medical therapy (GDMT) use according to target guideline recommendation

Methodological detailsmulticentre, national, Follow-up up to 24 months

Multicentre
National
Follow-up up to 24 months

No results yet. This paper sets out the design of a trial; its results are to come.

Reference

Authors: Inciardi RM, Vaduganathan M, Lombardi CM, Gussago C, Agostoni P, Ameri P, et al.
All 42 authors
Inciardi RM, Vaduganathan M, Lombardi CM, Gussago C, Agostoni P, Ameri P, Aspromonte N, Calò L, Cameli M, Carluccio E, Carugo S, Cipriani M, De Caterina R, De Ferrari GM, Emdin M, Fornaro A, Guazzi M, Iacoviello M, Imazio M, La Rovere MT, Leonardi S, Maccallini M, Masarone D, Moschini L, Palazzuoli A, Patti G, Pedretti RFE, Perrone Filardi P, Piepoli MF, Potena L, Salzano A, Sciacqua A, Senni M, Sinagra G, Specchia C, Taddei S, Vizza D, Savarese G, Rosano G, Volterrani M, Metra M, on behalf of the OPTIPHARM‐HF Investigators
Journal: European Journal of Heart Failure
Published: 23 Jun 2024
DOI: 10.1002/ejhf.3260
PubMed: 38923140
Registration: NCT06192524

Country: Italy
Topic: Heart failure & cardiomyopathies

Original publication

OPTImal PHARMacological Therapy for Patients with Heart Failure: Rationale and Design of the OPTIPHARM-HF Registry. Eur J Heart Fail. Published 23 June 2024. doi:10.1002/ejhf.3260

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →